531 related articles for article (PubMed ID: 20398445)
1. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
3. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
[TBL] [Abstract][Full Text] [Related]
4. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
5. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
6. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
[TBL] [Abstract][Full Text] [Related]
8. DNA-based molecular cytology for bladder cancer surveillance.
Jones JS
Urology; 2006 Mar; 67(3 Suppl 1):35-45; discussion 45-7. PubMed ID: 16530074
[TBL] [Abstract][Full Text] [Related]
9. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
10. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
Asali MG; Kaneti J; Manor E
Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
[TBL] [Abstract][Full Text] [Related]
11. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
13. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
14. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer.
Gofrit ON; Zorn KC; Silvestre J; Shalhav AL; Zagaja GP; Msezane LP; Steinberg GD
Urol Oncol; 2008; 26(3):246-9. PubMed ID: 18452813
[TBL] [Abstract][Full Text] [Related]
16. [Multiprobe FISH for enhanced prediction of recurrent bladder cancer].
Zellweger T; Benz G; Herzog M; Grilli B; Mihatsch MJ; Gasser TC; Bubendorf L
Verh Dtsch Ges Pathol; 2004; 88():194-8. PubMed ID: 16892552
[TBL] [Abstract][Full Text] [Related]
17. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.
Youssef RF; Schlomer BJ; Ho R; Sagalowsky AI; Ashfaq R; Lotan Y
Urol Oncol; 2012; 30(3):273-7. PubMed ID: 20451422
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
20. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
